Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study

NACompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2018

Conditions
Choroidal Neovascularization
Interventions
DRUG

bevacizumab

Injection technique: After lid speculum insertion and irrigation of the conjunctiva with 5% povidone-iodine, 0,05ml of bevacizumab will be inserted through the pars plana 3.5mm to 4.0mm posterior to the surgical limbus using a 30 gauge needle. After injection, topical antibiotics will be immediately applied in the injected eye. Immunosuppression: Corticosteroids will be prescribed (1mg/Kg/d) with tapering along 5 months. Immunosuppressive drug of choice is cyclosporine (3-5mg/Kg/d). In case of contraindication to cyclosporine use, azathioprine or mycophenolate mofetil will be prescribed.

Trial Locations (1)

Unknown

Hospital das Clínicas- University of Sao Paulo, São Paulo

All Listed Sponsors
collaborator

Fundação de Amparo à Pesquisa do Estado de São Paulo

OTHER_GOV

lead

University of Sao Paulo

OTHER

NCT02015351 - Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study | Biotech Hunter | Biotech Hunter